BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, July 25, 2026
Breaking News: Single-cell transcriptome study points to new drug targets for preeclampsiaSee today's BioWorld Science
Home » As target organ, liver can influence which metastases take
To read the full article sign up for free or sign in.
Cancer

As target organ, liver can influence which metastases take

July 26, 2024
By Mar de Miguel
Not all cancer cells that detach from the primary tumor and embark on a journey to another organ colonize it. To establish themselves, cells need specific conditions. Scientists at the Federal Institute of Technology Zurich (ETH Zurich) explored this hypothesis in the liver and identified a protein involved in metastatic transformation. Blocking it prevented liver metastasis. Their findings may have applications in other organs and various types of cancers.
BioWorld Science Cancer

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2026.
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 21, 2026
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld Science
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • Red CAR T cell on blue blackground

    To viral or not to viral: In vivo CAR T debates delivery tech

    BioWorld Asia
    The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing